{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"6.6","value":"4.1"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"5.2","value":"3.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Time from randomization to the earlier of disease progression or death. Patients alive and progression-free at last follow-up were censored.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemetrexed disodium 500 mg/m2 IV over 10 minutes and carboplatin to AUC 5 IV over 30 minutes on day 1 of a 21-day cycle.","id":"OG000","title":"Pemetrexed/Carboplatin"},{"description":"Pemetrexed disodium 500 mg/m2 IV over 10 minutes on day 1 and gemcitabine 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle.","id":"OG001","title":"Pemetrexed/Gemcitabine"}],"paramType":"MEDIAN","populationDescription":"The population consisted of all eligible, treated patients. 3 patients randomized to pemetrexed/gemcitabine who withdrew prior to treatment are excluded.","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months for 2 years, then every 6 months for 1 year","title":"Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}